Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations

References

• Abe, H., Kikuchi, S., Hayakawa, K., Iida, T., Nagahashi, N., Maeda, K., … Laquerre, S. G. (2011). Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Medicinal Chemistry Letters, 2(4), 320–324.
   PubMed Web of Science ®Google Scholar
• Barnes, T. A., O’Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017). Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Frontiers in Oncology, 7, 113.
   PubMed Web of Science ®Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. Journal of Physical Chemistry, 97(40), 10269–10280. doi: 10.1021/j100142a004
   Web of Science ®Google Scholar
• Camidge, D. R., Pao, W., & Sequist, L. V. (2014). Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nature Reviews. Clinical Oncology, 11(8), 473–481.
   PubMed Web of Science ®Google Scholar
• Case, D., Darden, T., Cheatham, T., III, Simmerling, C., Wang, J., Duke, R., … Kollman, P. (2012). AMBER 12. San Francisco, CA: University of California.
   Google Scholar
• Chen, L., Fu, W., Zheng, L., Liu, Z., & Liang, G. (2018). Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer. Journal of Medicinal Chemistry, 61 (10), 4290–4300. doi: 10.1021/acs.jmedchem.7b01310
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob, S. W., Jahnke, W., & Knapp, S. (2014). Novel approaches for targeting kinases: Allosteric inhibition, allosteric activation and pseudokinases. Future Medicinal Chemistry, 6(5), 541–561. doi: 10.4155/fmc.13.216
   PubMed Web of Science ®Google Scholar
• Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., … Pao, W. (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4(9), 1046–1061. doi: 10.1158/2159-8290.CD-14-0337
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N·log-(N) method for Ewald sums in large systems. Journal of Chemical Physics., 98(12), 10089–10092. doi: 10.1063/1.464397
   Web of Science ®Google Scholar
• Farasat, A., Rahbarizadeh, F., Hosseinzadeh, G., Sajjadi, S., Kamali, M., & Keihan, A. H. (2017). Affinity enhancement of nanobody binding to EGFR: In silico site-directed mutagenesis and molecular dynamics simulation approaches. Journal of Biomolecular Structure and Dynamics, 35(8), 1710–1728. doi: 10.1080/07391102.2016.1192065
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., … Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47(7), 1739–1749. doi: 10.1021/jm0306430
   PubMed Web of Science ®Google Scholar
• Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., … Mainz, D. T. (2006). Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. doi: 10.1021/jm051256o
   PubMed Web of Science ®Google Scholar
• Frisch, M., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Cheeseman, J., … Burant, J. (2004). Gaussian 03. Wallingford, CT: Gaussian, Inc.
   Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759. doi: 10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006). Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins: Structure, Function, and Bioinformatics, 65(3), 712–725. doi: 10.1002/prot.21123
   PubMed Web of Science ®Google Scholar
• Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. Journal of Chemical Information and Modeling, 51(1), 69–82. doi: 10.1021/ci100275a
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD: Visual molecular dynamics. Journal of Molecular Graphics, 14 (1), 33–38.
   PubMedGoogle Scholar
• Jia, Y., Yun, C., Park, E., Ercan, D., Manuia, M., Juarez, J., … Eck, M. J. (2016). Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors. Nature, 534(7605), 129–132. doi: 10.1038/nature17960
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 79(2), 926–935. doi: 10.1063/1.445869
   Web of Science ®Google Scholar
• Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large-scale conformational changes with a modified generalized Born model. Proteins: Structure, Function, and Bioinformatics, 55(2), 383–394. doi: 10.1002/prot.20033
   PubMed Web of Science ®Google Scholar
• Park, J., McDonald, J. J., Petter, R. C., & Houk, K. N. (2016). Molecular dynamics analysis of binding of kinase inhibitors to WT EGFR and the T790M mutant. Journal of Chemical Theory and Computation, 12(4), 2066–2078. doi: 10.1021/acs.jctc.5b01221
   PubMed Web of Science ®Google Scholar
• Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017). Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. European Journal of Medicinal Chemistry, 142, 32–47.
   PubMed Web of Science ®Google Scholar
• Reddy, P. S., Lokhande, K. B., Nagar, S., Reddy, V. D., Murthy, P. S., & Swamy, K. V. (2018). Molecular modeling, docking, dynamics and simulation of Gefitinib and its derivatives with EGFR in non-small cell lung cancer. Current Computer-Aided Drug Design, 14(3), 246–252. doi: 10.2174/1573409914666180228111433
   PubMed Web of Science ®Google Scholar
• Rocchia, W., Alexov, E., & Honig, B. (2001). Extending the applicability of the nonlinear Poisson–Boltzmann equation: Multiple dielectric constants and multivalent ions. Journal of Physical Chemistry B, 105(28), 6507–6514. doi: 10.1021/jp010454y
   Web of Science ®Google Scholar
• Ryckaert, J., Ciccotti, G., & Berendsen, H. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics., 23(3), 327–341. doi: 10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 7(3), 169–181.
   PubMed Web of Science ®Google Scholar
• Shepherd, F. A., Rodrigues, P. J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., … Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353(2), 123–132.
   PubMed Web of Science ®Google Scholar
• Shih, J. Y., Gow, C. H., & Yang, P. C. (2005). EGFR mutation conferring primary resistance to Gefitinib in non-small-cell lung cancer. New England Journal of Medicine, 353(2), 207–208.
   PubMed Web of Science ®Google Scholar
• Tan, C., Kumarakulasinghe, N. B., Huang, Y., Ang, Y. L. E., Choo, J. R., Goh, B., & Soo, R. A. (2018). Third generation EGFR TKIs: Current data and future directions. Molecular Cancer, 17(1), 29.
   PubMed Web of Science ®Google Scholar
• Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., … Oxnard, G. R. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560–562. doi: 10.1038/nm.3854
   PubMed Web of Science ®Google Scholar
• Tian, Y., Zhang, T., Long, L., Li, Z., Wan, S., Wang, G., … Zhang, J. (2018). Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors. European Journal of Medicinal Chemistry, 143, 182–199. doi: 10.1016/j.ejmech.2017.11.002
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general AMBER force field. Journal of Computational Chemistry, 25(9), 1157–1174.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Wan, S., Li, Z., Fu, Y., Wang, G., Zhang, J., & Wu, X. (2018). Design, synthesis, biological evaluation and molecular modeling of novel 1H -pyrazolo[3,4-d]pyrimidine derivatives as BRAF V600E and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 155, 210–228. doi: 10.1016/j.ejmech.2018.05.054
   PubMed Web of Science ®Google Scholar
• Weiser, J., Shenkin, P. S., & Still, W. C. (1999). Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry, 20(2), 217–230. doi: 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Web of Science ®Google Scholar
• Wu, X., Wang, Y., Wan, S., & Zhang, J. (2017). Investigation on the binding mechanism of Loratinib with the c-ROS oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations. Journal of Biomolecular Structure and Dynamics, 1–8. [Published Online]. doi: 10.1080/07391102.2017.1378127.
   PubMed Web of Science ®Google Scholar
• Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., … Eck, M. J. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070–2075.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews. Cancer, 9(1), 28–39.
   PubMed Web of Science ®Google Scholar
• Zhao, P., Yao, M., Zhu, S., Chen, J., & Yun, C. (2018). Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045. Biochemical and Biophysical Research Communications, 502(3), 332–337.
   PubMed Web of Science ®Google Scholar